MAO-B-IN-9 is a selective inhibitor of monoamine oxidase B (MAO-B), making it a valuable compound in neuroscience research, particularly in studies related to neurodegenerative diseases such as Parkinson’s disease. By inhibiting MAO-B, it reduces the breakdown of dopamine in the brain, helping to maintain higher dopamine levels, which is critical for motor control and cognitive function. This compound is used in preclinical studies to evaluate neuroprotection, dopaminergic activity, and potential disease-modifying effects. Its selectivity minimizes interactions with MAO-A, reducing the risk of dietary restrictions and side effects associated with non-selective MAO inhibitors. MAO-B-IN-9 serves as a tool compound for validating MAO-B as a therapeutic target and may support the development of new treatments for age-related neurological disorders.